SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2894)8/1/2013 1:15:51 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
 
Cool.

There's a study around here someplace, maybe the indications-cancer thread or the INFI thread? From BARTS, London. Other misc. stuff leaning same direction, that alternative isoforms mediate resistance to delta inhibitors.

Calistoga (GILD) got it all rolling, and Clovis is the flavor of the day.

GILD
INFI
CLVS

Any other advanced candidates?

Best!

Rick



To: Biotech Jim who wrote (2894)8/1/2013 3:20:15 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 3202
 
By the end of the conference call, a 093 plus ruxolitinib combo, lymphoma, seemed like a telegraphed next-step. No?

Cool re. Madison. I'm presuming that biotech took you there, or have you retired and the proximity to biotech is simply a coincidence?

Would be so cool to have a local fishing hole. Good luck with the move!

Rick


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News